中国防痨杂志 ›› 2021, Vol. 43 ›› Issue (1): 87-90.doi: 10.3969/j.issn.1000-6621.2021.01.016
收稿日期:
2020-12-03
出版日期:
2021-01-10
发布日期:
2021-01-12
通信作者:
邓国防
E-mail:jxxk1035@yeah.net
基金资助:
YANG Min, FU Liang, DENG Guo-fang()
Received:
2020-12-03
Online:
2021-01-10
Published:
2021-01-12
Contact:
DENG Guo-fang
E-mail:jxxk1035@yeah.net
摘要:
据估算,至2045年全球糖尿病患者可能会增长至7亿例,大约16%的结核病患者会并发糖尿病,结核病并发糖尿病(TB-DM)的双重负担会成为一个重大的全球性公共卫生问题。糖尿病(包括1型和2型)会增加活动性结核病的风险,与单纯结核病患者相比,TB-DM患者的治疗转归更差。糖尿病发病率的增长不但将增加罹患结核病的患病风险,还对结核病的治疗管理构成严重挑战。作者就TB-DM的双向筛查、相互影响、治疗和管理、药品相互作用等内容进行综述。
杨敏, 付亮, 邓国防. 结核病并发糖尿病治疗管理相关进展[J]. 中国防痨杂志, 2021, 43(1): 87-90. doi: 10.3969/j.issn.1000-6621.2021.01.016
YANG Min, FU Liang, DENG Guo-fang. Progress in the treatment and management of tuberculosis complicated with diabetes[J]. Chinese Journal of Antituberculosis, 2021, 43(1): 87-90. doi: 10.3969/j.issn.1000-6621.2021.01.016
[1] | World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020. |
[2] |
Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract, 2018,138:271-281. doi: 10.1016/j.diabres.2018.02.023.
doi: 10.1016/j.diabres.2018.02.023 URL pmid: 29496507 |
[3] |
Workneh MH, Bjune GA, Yimer SA. Prevalence and associa-ted factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. PLoS One, 2017,12(4):e0175925. doi: 10.1371/journal.pone.0175925.
doi: 10.1371/journal.pone.0175925 URL pmid: 28430796 |
[4] |
Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol, 2014,44(3):617-626. doi: 10.1002/eji.201344301.
URL pmid: 24448841 |
[5] |
Jiménez-Corona ME, Cruz-Hervert LP, García-García L, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax, 2013,68(3):214-220. doi: 10.1136/thoraxjnl-2012-201756.
doi: 10.1136/thoraxjnl-2012-201756 URL pmid: 23250998 |
[6] |
Viswanathan V, Kumpatla S, Aravindalochanan V, et al. Prevalence of diabetes and pre-diabetes and associated risk factors among tuberculosis patients in India. PLoS One, 2012,7(7):e41367. doi: 10.1371/journal.pone.0041367.
doi: 10.1371/journal.pone.0041367 URL pmid: 22848473 |
[7] |
Lee PH, Fu H, Lai TC, et al. Glycemic Control and the Risk of Tuberculosis: A Cohort Study. PLoS Med, 2016,13(8):e1002072. doi: 10.1371/journal.pmed.1002072.
doi: 10.1371/journal.pmed.1002072 URL pmid: 27505150 |
[8] |
Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2·3 million patients with tuberculosis. Lancet Glob Health, 2019,7(4):e448-460. doi: 10.1016/S2214-109X(18)30487-X.
doi: 10.1016/S2214-109X(18)30487-X URL pmid: 30819531 |
[9] |
Boillat-Blanco N, Ramaiya KL, Mganga M, et al. Transient Hyperglycemia in Patients With Tuberculosis in Tanzania: Implications for Diabetes Screening Algorithms. J Infect Dis, 2016,213(7):1163-1172. doi: 10.1093/infdis/jiv568.
doi: 10.1093/infdis/jiv568 URL pmid: 26609005 |
[10] |
Grint D, Alisjhabana B, Ugarte-Gil C, et al. Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa. Bull World Health Organ, 2018,96(11):738-749. doi: 10.2471/BLT.17.206227.
doi: 10.2471/BLT.17.206227 URL pmid: 30455529 |
[11] | Lin Y, Harries AD, Kumar AMV, et al. Management of diabetes mellitus-tuberculosis: a guide to the essential practice. Paris: International Union Against Tuberculosis and Lung Disease, 2019. |
[12] |
Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J, 2015,46(6):1563-1576. doi: 10.1183/13993003.01245-2015.
doi: 10.1183/13993003.01245-2015 URL pmid: 26405286 |
[13] |
Wang JY, Lee MC, Shu CC, et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months? Chest, 2015,147(2):520-528. doi: 10.1378/chest.14-0918.
doi: 10.1378/chest.14-0918 URL pmid: 25255302 |
[14] |
Liu Q, Li W, Xue M, et al. Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis. Sci Rep, 2017,7(1):1090. doi: 10.1038/s41598-017-01213-5.
URL pmid: 28439071 |
[15] |
Ronacher K, van Crevel R, Critchley JA, et al. Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 2: Underlying Biologic Mecha-nisms. Chest, 2017,152(1):174-180. doi: 10.1016/j.chest.2017.02.032.
doi: 10.1016/j.chest.2017.02.032 URL pmid: 28434937 |
[16] |
Huaman MA, Kryscio RJ, Fichtenbaum CJ, et al. Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis. Epidemiol Infect, 2017,145(7):1363-1367. doi: 10.1017/S0950268817000279.
doi: 10.1017/S0950268817000279 URL pmid: 28202093 |
[17] |
Chung WS, Lin CL, Hung CT, et al. Tuberculosis increases the subsequent risk of acute coronary syndrome: a nationwide population-based cohort study. Int J Tuberc Lung Dis, 2014,18(1):79-83. doi: 10.5588/ijtld.13.0288.
URL pmid: 24365557 |
[18] |
Sheu JJ, Chiou HY, Kang JH, et al. Tuberculosis and the risk of ischemic stroke: a 3-year follow-up study. Stroke, 2010,41(2):244-249. doi: 10.1161/STROKEAHA.109.567735.
doi: 10.1161/STROKEAHA.109.567735 URL pmid: 20035070 |
[19] |
Faurholt-Jepsen D, Range N, PrayGod G, et al. Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania. Trop Med Int Health, 2013,18(7):822-829. doi: 10.1111/tmi.12120.
doi: 10.1111/tmi.12120 URL pmid: 23648145 |
[20] |
Reed GW, Choi H, Lee SY, et al. Impact of diabetes and smoking on mortality in tuberculosis. PLoS One, 2013,8(2):e58044. doi: 10.1371/journal.pone.0058044.
doi: 10.1371/journal.pone.0058044 URL pmid: 23469139 |
[21] |
van Crevel R, Dockrell HM, TANDEM Consortium. TANDEM: understanding diabetes and tuberculosis. Lancet Diabetes Endocrinol, 2014,2(4):270-272. doi: 10.1016/S2213-8587(14)70011-7.
doi: 10.1016/S2213-8587(14)70011-7 URL pmid: 24703039 |
[22] |
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008,359(15):1577-1589. doi: 10.1056/NEJMoa0806470.
doi: 10.1056/NEJMoa0806470 URL pmid: 18784090 |
[23] |
Mushtaq A. Tuberculosis in diabetes: insidious and neglected. Lancet Respir Med, 2019,7(6):483. doi: 10.1016/S2213-2600(19)30119-5.
doi: 10.1016/S2213-2600(19)30119-5 URL pmid: 31003965 |
[24] |
Lachmandas E, Eckold C, Böhme J, et al. Metformin Alters Human Host Responses to Mycobacterium tuberculosis in Healthy Subjects. J Infect Dis, 2019,220(1):139-150. doi: 10.1093/infdis/jiz064.
doi: 10.1093/infdis/jiz064 URL pmid: 30753544 |
[25] |
Tseng CH. Metformin Decreases Risk of Tuberculosis Infection in Type 2 Diabetes Patients. J Clin Med, 2018,7(9):264. doi: 10.3390/jcm7090264.
doi: 10.3390/jcm7090264 URL |
[26] |
Pan SW, Yen YF, Kou YR, et al. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment. Chest, 2018,153(6):1347-1357. doi: 10.1016/j.chest.2017.11.040.
doi: 10.1016/j.chest.2017.11.040 URL pmid: 29253553 |
[27] |
Vrieling F, Ronacher K, Kleynhans L, et al. Patients with Concurrent Tuberculosis and Diabetes Have a Pro-Atherogenic Plasma Lipid Profile. EBioMedicine, 2018,32:192-200. doi: 10.1016/j.ebiom.2018.05.011.
doi: 10.1016/j.ebiom.2018.05.011 URL pmid: 29779698 |
[28] |
Pan SC, Chen CC, Chiang YT, et al. Health Care Visits as a Risk Factor for Tuberculosis in Taiwan: A Population-Based Case-Control Study. Am J Public Health, 2016,106(7):1323-1328. doi: 10.2105/AJPH.2016.303152.
doi: 10.2105/AJPH.2016.303152 URL pmid: 27196655 |
[29] |
Zhang Q, Xiao H, Sugawara I. Tuberculosis complicated by diabetes mellitus at shanghai pulmonary hospital, china. Jpn J Infect Dis, 2009,62(5):390-391.
URL pmid: 19762992 |
[30] |
Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis, 2006,43(7):848-854. doi: 10.1086/507543.
doi: 10.1086/507543 URL pmid: 16941365 |
[31] |
Sun H, Scott DO. Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics. Chem Biol Interact, 2011,194(2/3):159-167. doi: 10.1016/j.cbi.2011.08.011.
doi: 10.1016/j.cbi.2011.08.011 URL |
[32] |
Riza AL, Pearson F, Ugarte-Gil C, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol, 2014,2(9):740-753. doi: 10.1016/S2213-8587(14)70110-X.
doi: 10.1016/S2213-8587(14)70110-X URL pmid: 25194887 |
[33] |
Kewcharoenwong C, Prabowo SA, Bancroft GJ, et al. Gliben-clamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 Polarization. Front Immunol, 2018,9:2109. doi: 10.3389/fimmu.2018.02109.
doi: 10.3389/fimmu.2018.02109 URL pmid: 30283449 |
[34] |
Critchley JA, Restrepo BI, Ronacher K, et al. Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 1: Epidemiology and Clinical Management. Chest, 2017,152(1):165-173. doi: 10.1016/j.chest.2017.04.155.
doi: 10.1016/j.chest.2017.04.155 URL pmid: 28434936 |
[35] |
van Crevel R, Koesoemadinata R, Hill PC, et al. Clinical management of combined tuberculosis and diabetes. Int J Tuberc Lung Dis, 2018,22(12):1404-1410. doi: 10.5588/ijtld.18.0340.
doi: 10.5588/ijtld.18.0340 URL pmid: 30606312 |
[1] | 王前, 李涛, 杜昕, 倪妮, 赵雁林, 张慧. 2015—2019年全国肺结核报告发病情况分析[J]. 中国防痨杂志, 2021, 43(2): 107-112. |
[2] | 邝浩斌, 谢育红, 冯治宇, 覃红娟, 廖雅怡, 汪敏, 张宏, 袁园, 吴迪, 陈泽莹, 谭守勇. 2014—2019年广州市耐多药肺结核管理策略实施效果分析[J]. 中国防痨杂志, 2021, 43(2): 113-118. |
[3] | 张广川, 赖铿, 杜雨华, 吴桂锋, 雷宇, 沈鸿程, 杨洁莹, 林莹, 钟敏儿, 钟芷晴, 刘丽, 李铁钢. 2014—2019年广州市涂阳肺结核患者流行特征分析[J]. 中国防痨杂志, 2021, 43(2): 119-125. |
[4] | 叶锦欣, 许琳, 陈金瓯, 邱玉冰, 律彤. 2011—2019年云南省结核病并发艾滋病患者抗结核治疗期间死亡影响因素分析[J]. 中国防痨杂志, 2021, 43(2): 126-131. |
[5] | 王佩, 赵国连, 雷倩, 郑丹, 崔晓利, 周俊. 荧光PCR探针熔解曲线法与微孔板法检测MTB耐药性的临床应用比较[J]. 中国防痨杂志, 2021, 43(2): 132-138. |
[6] | 陆霓虹, 孙娅萍, 金媛, 夏加伟, 杨永锐. 早期分泌抗原靶6及基质金属蛋白酶9评估结核性毁损肺严重程度的应用价值[J]. 中国防痨杂志, 2021, 43(2): 139-142. |
[7] | 崔晓敬, 魏栋, 王春雷, 曹彬. 分子生物学和液体培养方法提高综合医院结核病病原学诊断能力的价值[J]. 中国防痨杂志, 2021, 43(2): 143-146. |
[8] | 王秀军, 刘秋月, 陈晓凤, 于磊, 马艳, 韩芬. 基于非标记定量技术的继发性肺结核患者血浆蛋白质组学研究[J]. 中国防痨杂志, 2021, 43(2): 159-165. |
[9] | 季乐财, 张乐平, 吕建文, 李晓定, 邹小飞, 朴玮. 全基因组测序预测深圳市耐多药结核分枝杆菌的耐药性分析[J]. 中国防痨杂志, 2021, 43(2): 166-170. |
[10] | 费骏, 石仕元, 胡胜平, 胡德新, 张晨威. 经皮质骨轨迹螺钉在腰椎结核病椎间固定的生物力学研究[J]. 中国防痨杂志, 2021, 43(2): 171-177. |
[11] | 米洁, 薛勇, 白雪娟, 吴雪琼. 淋巴细胞亚群检测在结核病诊疗中的应用进展[J]. 中国防痨杂志, 2021, 43(2): 178-185. |
[12] | 郭倩, 申晨, 申阿东. 干细胞与结核分枝杆菌交互作用的研究进展[J]. 中国防痨杂志, 2021, 43(2): 186-189. |
[13] | 曹鑫宇, 薛秒, 文艳, 刘莉. 抗结核药物性肝损伤易感基因研究进展[J]. 中国防痨杂志, 2021, 43(2): 190-193. |
[14] | 刘文峰, 周琳, 徐天亮, 易槐明, 王勇, 王谦信. 浙江省常山县“移动结核门诊”服务在结核病防控中的实施效果评价[J]. 中国防痨杂志, 2021, 43(1): 100-102. |
[15] | 国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 国家代谢性疾病临床医学研究中心, 中南大学湘雅二医院, 中国防痨协会, 《中国防痨杂志》编辑委员会. 结核病与糖尿病共病的治疗管理专家共识[J]. 中国防痨杂志, 2021, 43(1): 12-22. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||